Melanoma/Skin Cancer

Top Story

Entrectinib induces ‘rapid and durable’ responses in pediatric tumors with gene fusions

Entrectinib induces ‘rapid and durable’ responses in pediatric tumors with gene fusions
May 16, 2019

Read the Perspective from Darrell Yamashiro, MD, PhD

Feature

Single-dose pembrolizumab may induce remission in advanced melanoma

May 15, 2019
Patients with advanced melanoma appeared to experience durable remission with single-dose pembrolizumab initiated 3 weeks before surgery, according to study results…
In the Journals

Tumor thickness, location of primary melanoma affects recurrence rates

May 9, 2019
Researchers suggest that approximately 13% of patients with a high-risk primary melanoma may develop recurrence within 2 years, and informed clinical follow-up should…

Seven important updates for Skin Cancer Awareness Month

May 3, 2019
Skin Cancer Awareness Month, observed every May, is intended to educate the public about the dangers of UV radiation and encourage sun-safe habits. In conjunction with…
More Headlines »
CME

Sickle Cell Disease Forum: Innovation in Drug Development and Emerging Science

This activity is supported by an educational grant from Bristol-Myers Squibb.

For patients diagnosed with metastatic melanoma, the lifetime incidence of brain metastasis is more than 50% and is…
More »
Video
FDA News

VIDEO: BRAF-MEK combination represents ‘important new therapy’ for melanoma

June 27, 2018
More »
Resource Centers